Charles River Laboratories International, Inc. (CRL)

NYSE · Health Care · market cap 8.70B

Share price

$281.67

At the last nightly close

Intrinsic value

$103.35

Range $103.35 – $210.05 — the conservative figure is the low end.

Margin of safety

-63.3%

($103.35 − $281.67) ÷ $281.67

EV / EBIT

49.2

On the median operating profit of 15 fiscal years through 2025.

How these numbers are computed

The valuations are calculated in Python from filed accounts, not written by a language model. Three methods run side by side: earnings power value, which capitalises a normalised operating profit; a free-cash-flow model; and the Graham Number as an asset-side cross-check. The conservative figure above is the low end of what they agree on.

The frame gives no credit for growth. A company that compounds will therefore read as expensive against it — that is deliberate. It is a price-discipline floor, not a price target, and it is not a view on what the shares will do.

The EV/EBIT ranking uses the median operating profit of up to fifteen fiscal years — a full cycle — where the free screeners use the last twelve months. When the data cannot support a method, the figure reads n/a rather than a number: a free-cash-flow valuation on a bank, a PEG on erratic earnings, a multiple on a company with no operating profit to speak of.

Fundamentals from SEC EDGAR. Prices, market data and technicals from yfinance. Valuation computed 2026-09-03.

Key metrics

Price / earningsn/a
Price / book4.7
EV / EBITDA18.8
FCF / EV+1.8%
Return on equity-7.5%
Return on assets+4.1%
Debt / equity1.05
Gross margin+34.6%

Market position

52-week high$298.58
52-week low$145.57
From 52-week high-5.7%
RSI (14)54.5
200-day moving average$213.44

Annual financials

PeriodRevenueOperating incomeNet incomeEPSFree cash flow
2025-FY4.02B401.1M-144.3M-2.91518.5M
2024-FY4.05B442.3M10.3M0.20501.6M
2023-FY4.13B617.3M474.6M9.27365.4M
2022-FY3.98B651.0M486.2M9.57294.9M
2021-FY3.54B589.9M391.0M7.60532.0M

Filed figures from SEC EDGAR, in the reporting currency.

Next earnings

Q4 2026 expectedNovember 4, 2026
Consensus EPS estimate2.95

Recent news

The figures above are the arithmetic. To see what a board of eight AI agents makes of them — macro, sector, filings, news and a devil's advocate whose only job is to attack the thesis — run the full analysis on CRL.

Run the board on CRL

10 free analyses · no signup, no card

This page presents computed figures and filed financial data for information only. It is not investment advice, not a recommendation to buy or sell any security, and not a statement about what these shares will do. Sperio is a research tool, not an investment adviser. Figures are derived automatically from public filings and market data and may be incomplete, out of date or wrong. See the Terms & Disclaimer.